FMP
Mirati Therapeutics, Inc.
MRTX
NASDAQ
Inactive Equity
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
58.7 USD
-0.1 (-0.17%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Charles M. Baum M.D., Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.mirati.comexchange
NASDAQ
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Thera...
CIK
0001576263
ISIN
US60468T1051
CUSIP
60468T105
Address
3545 Cray Court
Phone
858 332 3410
Country
US
Employee
587
IPO Date
Jul 15, 2013
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
MRTX Financial Summary
CIK
0001576263
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
60468T105
ISIN
US60468T1051
Country
US
Price
58.7
Beta
0.77
Volume Avg.
1.78M
Market Cap
4.12B
Shares
-
52-Week
27.3-64.41
DCF
-4.13
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-4.82
P/B
-
Website
https://www.mirati.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest MRTX News
It looks like there's no news available.
